Sector News

Lilly CEO Sees Light After a Difficult Year

October 20, 2014
Life sciences
Eli Lilly & Co. is deep into what Chief Executive John C. Lechleiter calls the “toughest year” in the drug maker’s 138-year history. Revenue at Lilly has plunged because of generic competition that followed patent expirations for several of its top-selling drugs, including the antidepressant Cymbalta.
 
The 61-year-old Dr. Lechleiter, meanwhile, faced one of his own toughest years in 2013: He took a two-month medical leave to undergo and recover from surgery to repair a damaged aorta.
 
Dr. Lechleiter, who joined Lilly as a chemist in 1979 and took over as CEO in 2008, says both he and Lilly are on the mend. The company has received regulatory approval to sell three new drugs—two for diabetes and one for gastric cancer—and has more experimental drugs in late-stage clinical testing.
 
In an interview at company headquarters in Indianapolis, the CEO talked about challenges facing Lilly and the health-care industry, including his desire for corporate tax reforms, and the impact of the Affordable Care Act on pharmaceutical makers. 
 
> Read the interview on the Wall Street Journal website
 
By Peter Loftus
 

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend